Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12000239 | 0.86 | MAPT (0.61) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL1520260 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL5924831 | 0.73 | NPC1 (0.80) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL1668058 | 0.71 | NPC1 (0.71) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL29559386 | 0.70 | MAPT (0.55) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL5924655 | 0.65 | NPC1 (0.43) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL23657726 | 0.63 | MAPT (0.83) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL12806939 | 0.62 | PIM3 (0.51) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL938913 | 0.61 | MPO (0.41) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL3083301 | 0.61 | PIM3 (0.54) | MAPTMEN1KMT2AL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329727-B2 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790730-B2 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| US-20090208456-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090208456-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | GILEAD SCIENCES, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | CYP3A5, TPMT, ZC3HAV1 | MAPT 4389/4885MEN1 3617/4885KMT2A 2165/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | MAPT 4159/4885MEN1 3448/4885KMT2A 2777/4885 |
| US-20090208456-A1 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation | TYMP, DPYD, TYMS | MAPT 4092/4885MEN1 3483/4885KMT2A 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.